Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.52 |
| ▸ | AHCY | P23526 | 8/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.48 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11703712 | 0.93 | ADORA2A (0.54) | ADORA2AADORA3AHCYADORA2BHSP90B1 | |
| SCHEMBL6298549 | 0.92 | ADORA2A (0.53) | ADORA2AADORA3AHCYADORA2BHSP90B1 | |
| SCHEMBL11701245 | 0.91 | ADORA2A (0.53) | ADORA2AADORA3AHCYADORA2BHSP90B1 | |
| SCHEMBL3411985 | 0.88 | ADORA2A (0.53) | ADORA2AADORA3AHCYADORA2BHSP90B1 | |
| SCHEMBL6864727 | 0.87 | ADORA2A (0.54) | ADORA2AADORA3AHCYADORA2BHSP90B1 | |
| SCHEMBL3411906 | 0.86 | ADORA2A (0.50) | ADORA2AADORA3AHCY | |
| SCHEMBL10439705 | 0.85 | ADORA2A (0.54) | ADORA2AADORA3AHCYADORA2BKMT2A | |
| SCHEMBL6299609 | 0.84 | ADORA2A (0.54) | ADORA2AADORA3AHCYADORA2BTSHR | |
| SCHEMBL30544925 | 0.84 | ADORA2A (0.49) | ADORA2AADORA3AHCYADORA2BHSP90B1 | |
| SCHEMBL3408365 | 0.84 | ADORA2A (0.54) | ADORA2AADORA3AHCYADORA2BTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1878470-B1 | Skin depigmentation method | OREAL (FR) | 2009-03-11 | — | — | EP | claimed |
| EP-1878470-A1 | Skin depigmentation method | L'Oréal (FR) | 2008-01-16 | — | — | EP | claimed |
| US-20070258921-A1 | PROCESS FOR DEPIGMENTING THE SKIN | L'OREAL (FR) | 2007-11-08 | — | — | US | claimed |
| EP-1847547-A1 | Anti-wrinkle cosmetic composition | L'Oréal (FR) | 2007-10-24 | — | — | EP | claimed |
| US-20070237734-A1 | ANTI-WRINKLE COSMETIC COMPOSITION | L'OREAL (FR) | 2007-10-11 | — | — | US | claimed |
| EP-2204154-B1 | Association of monosaccharides and adenosine and its cosmetic use | ORÉAL L (FR) | 2016-10-12 | — | — | EP | disclosed |
| EP-2204154-A1 | Association of monosaccharides and adenosine and its cosmetic use | L'OREAL (FR) | 2010-07-07 | — | — | EP | disclosed |
| US-20100168049-A1 | COMBINATION OF MONOSACCHARIDES AND ADENOSINE AND USE THEREOF | L'OREAL (FR) | 2010-07-01 | — | — | US | disclosed |
| EP-1878470-B1 | Skin depigmentation method | OREAL (FR) | 2009-03-11 | — | — | EP | disclosed |
| EP-1878470-A1 | Skin depigmentation method | L'Oréal (FR) | 2008-01-16 | — | — | EP | disclosed |
| US-20070258921-A1 | PROCESS FOR DEPIGMENTING THE SKIN | L'OREAL (FR) | 2007-11-08 | — | — | US | disclosed |
| EP-1847547-A1 | Anti-wrinkle cosmetic composition | L'Oréal (FR) | 2007-10-24 | — | — | EP | disclosed |
| US-20070237734-A1 | ANTI-WRINKLE COSMETIC COMPOSITION | L'OREAL (FR) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258921-A1 | PROCESS FOR DEPIGMENTING THE SKIN | TYR, CUTA, NQO1 | ADORA2A 3810/4885ADORA3 4081/4885AHCY 2788/4885 |
| US-20070237734-A1 | ANTI-WRINKLE COSMETIC COMPOSITION | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA3 2/4885AHCY 252/4885 |
| US-20100168049-A1 | COMBINATION OF MONOSACCHARIDES AND ADENOSINE AND USE THEREOF | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA3 3/4885AHCY 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.